Indivior revenue falls as opioid addiction drug's market share plummets

(Reuters) - Indivior Plc reported a 19% slump in third-quarter revenue on Thursday as the British drugmaker's best-selling opioid addiction treatment lost more than half of its market share to cheaper generic rivals in the United States.The company's shares were down 6.5% after profit also fell by double-digits percentage. The stock has lost nearly two-thirds of its value this year as the London-listed firm faces competition from copycat drugs as well as a $3 billion (£2.3 billion) U.S. fine..